FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004454490> ?p ?o ?g. }

• W2004454490 endingPage "501" @default.
• W2004454490 startingPage "492" @default.
• W2004454490 abstract "We examined the ex vivo platelet aggregation profiles of patients who underwent percutaneous coronary intervention and received either abciximab, ticlopidine, or both agents.The trial was a prospective, nonrandomized, single-center, open-label study of 42 patients undergoing percutaneous coronary intervention who received the following regimens: group 1, abciximab (0.25 mg/kg bolus and 12-hour, 0.125 microg/kg per minute infusion); group 2, ticlopidine (250 mg twice daily for 14 consecutive days, initiated 12 to 18 hours before intervention); group 3, abciximab plus ticlopidine initiated 12 to 18 hours before procedure; and group 4, abciximab plus ticlopidine initiated 72 to 96 hours before procedure. Platelet aggregation measurements to adenosine diphosphate (ADP) and a thrombin receptor activating peptide (TRAP, 8 micromol/L) were obtained before ticlopidine treatment, after initiation of ticlopidine, and immediately before abciximab treatment and intervention, then at several time periods after onset of abciximab treatment. Platelet surface abciximab levels were monitored by flow cytometry.Neither ticlopidine regimen resulted in appreciable platelet inhibition before intervention and before administration of abciximab. In the ticlopidine-only arm, suppression of platelet aggregation to the weakest stimuli (5 micromol/L ADP; 23% +/- 7.5%) was detected within 24 hours after intervention, with maximal inhibition to both 5 and 20 micromol/L ADP observed 7 days after intervention (48% +/- 7.9% and 18% +/- 8.7%, respectively). In contrast, ticlopidine marginally suppressed TRAP-mediated platelet activation at times when maximal effects on ADP-mediated platelet aggregation were evident. Neither ticlopidine regimen appreciably enhanced platelet inhibition during or shortly after cessation of abciximab treatment. For all 3 abciximab treatment arms, profound inhibition of ADP-induced (>80%) and TRAP-induced (>65%) platelet aggregation was observed 2 hours after treatment. In the abciximab-only arm, platelet aggregation responses gradually recovered, with the rate of response directly proportional to the strength of stimuli. However, in the ticlopidine plus abciximab arms, recovery of platelet aggregation at later times (7 and 14 days) reached a plateau and reflected the extent of inhibition observed in ticlopidine-treated patients. No difference in the clearance of surface-bound abciximab from circulating platelets was observed between the abciximab and abciximab plus ticlopidine arms.Concomitant abciximab plus ticlopidine treatment yields a platelet inhibition profile that is a composite of the effects of the 2 agents. In the early stages of treatment, inhibition of ex vivo platelet aggregation was mediated primarily by abciximab; effects were more moderate and were predominately mediated by ticlopidine." @default.
• W2004454490 created "2016-06-24" @default.
• W2004454490 creator A5003852576 @default.
• W2004454490 creator A5013675555 @default.
• W2004454490 creator A5030540014 @default.
• W2004454490 creator A5039754301 @default.
• W2004454490 creator A5067335761 @default.
• W2004454490 creator A5068898448 @default.
• W2004454490 creator A5072855474 @default.
• W2004454490 creator A5074380484 @default.
• W2004454490 creator A5085434047 @default.
• W2004454490 date "2000-09-01" @default.
• W2004454490 modified "2023-09-27" @default.
• W2004454490 title "Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions" @default.
• W2004454490 cites W1964910597 @default.
• W2004454490 cites W1974267587 @default.
• W2004454490 cites W1982284371 @default.
• W2004454490 cites W1995552818 @default.
• W2004454490 cites W1995798630 @default.
• W2004454490 cites W2000678106 @default.
• W2004454490 cites W2012214760 @default.
• W2004454490 cites W2017804207 @default.
• W2004454490 cites W2020951163 @default.
• W2004454490 cites W2023252309 @default.
• W2004454490 cites W2025410012 @default.
• W2004454490 cites W2026202162 @default.
• W2004454490 cites W2037465103 @default.
• W2004454490 cites W2038819610 @default.
• W2004454490 cites W2048171314 @default.
• W2004454490 cites W2052899600 @default.
• W2004454490 cites W2068916210 @default.
• W2004454490 cites W2072472280 @default.
• W2004454490 cites W2074762647 @default.
• W2004454490 cites W2080649274 @default.
• W2004454490 cites W2085527069 @default.
• W2004454490 cites W2086887906 @default.
• W2004454490 cites W2087339238 @default.
• W2004454490 cites W2091054752 @default.
• W2004454490 cites W2112799238 @default.
• W2004454490 cites W2137499117 @default.
• W2004454490 cites W2230838014 @default.
• W2004454490 cites W2319834083 @default.
• W2004454490 cites W2327850977 @default.
• W2004454490 cites W2329490408 @default.
• W2004454490 cites W2395313915 @default.
• W2004454490 cites W2404214979 @default.
• W2004454490 cites W2416434554 @default.
• W2004454490 cites W2436774132 @default.
• W2004454490 cites W2473221701 @default.
• W2004454490 cites W3022148767 @default.
• W2004454490 cites W311320695 @default.
• W2004454490 cites W4298870436 @default.
• W2004454490 doi "https://doi.org/10.1067/mhj.2000.109220" @default.
• W2004454490 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10966553" @default.
• W2004454490 hasPublicationYear "2000" @default.
• W2004454490 type Work @default.
• W2004454490 sameAs 2004454490 @default.
• W2004454490 citedByCount "16" @default.
• W2004454490 countsByYear W20044544902012 @default.
• W2004454490 countsByYear W20044544902013 @default.
• W2004454490 countsByYear W20044544902020 @default.
• W2004454490 crossrefType "journal-article" @default.
• W2004454490 hasAuthorship W2004454490A5003852576 @default.
• W2004454490 hasAuthorship W2004454490A5013675555 @default.
• W2004454490 hasAuthorship W2004454490A5030540014 @default.
• W2004454490 hasAuthorship W2004454490A5039754301 @default.
• W2004454490 hasAuthorship W2004454490A5067335761 @default.
• W2004454490 hasAuthorship W2004454490A5068898448 @default.
• W2004454490 hasAuthorship W2004454490A5072855474 @default.
• W2004454490 hasAuthorship W2004454490A5074380484 @default.
• W2004454490 hasAuthorship W2004454490A5085434047 @default.
• W2004454490 hasConcept C126322002 @default.
• W2004454490 hasConcept C126894567 @default.
• W2004454490 hasConcept C141071460 @default.
• W2004454490 hasConcept C2777265216 @default.
• W2004454490 hasConcept C2777849778 @default.
• W2004454490 hasConcept C2777871224 @default.
• W2004454490 hasConcept C2778905298 @default.
• W2004454490 hasConcept C2780400711 @default.
• W2004454490 hasConcept C3018697912 @default.
• W2004454490 hasConcept C42219234 @default.
• W2004454490 hasConcept C500558357 @default.
• W2004454490 hasConcept C71924100 @default.
• W2004454490 hasConcept C89560881 @default.
• W2004454490 hasConcept C98274493 @default.
• W2004454490 hasConceptScore W2004454490C126322002 @default.
• W2004454490 hasConceptScore W2004454490C126894567 @default.
• W2004454490 hasConceptScore W2004454490C141071460 @default.
• W2004454490 hasConceptScore W2004454490C2777265216 @default.
• W2004454490 hasConceptScore W2004454490C2777849778 @default.
• W2004454490 hasConceptScore W2004454490C2777871224 @default.
• W2004454490 hasConceptScore W2004454490C2778905298 @default.
• W2004454490 hasConceptScore W2004454490C2780400711 @default.
• W2004454490 hasConceptScore W2004454490C3018697912 @default.
• W2004454490 hasConceptScore W2004454490C42219234 @default.
• W2004454490 hasConceptScore W2004454490C500558357 @default.
• W2004454490 hasConceptScore W2004454490C71924100 @default.
• W2004454490 hasConceptScore W2004454490C89560881 @default.

• next